Be part of an industrial knowledge cluster
unrivalled in Europe

The cluster encompasses every stage of ophthalmic drug development and every sector of activity in the field.

 

Main public laboratories pursuing research linked to ophthalmology:

- Centre Antoine Lacassagne

- Institut de Pharmacologie Moléculaire et Cellulaire

- INRIA

- Laboratoire de psychologie expérimentale quantitative

Join Ophta Biotech, a collaborative platform serving the visually impaired

Fact: a growing and ageing population is leading to increased demand for ophthalmology care and treatment

Ophta biotech: founded in February 2008, the association is made up of 40 members (research laboratories, manufacturers, ophthalmologists, hospitals, universities and patients' associations) in the Alpes-Maritimes, Monaco and Corsica

 

Objective: to promote the emergence of new projects and tools to combat the entire range of pathologies affecting visually impaired patients.

Ophta Biotech's strengths: a unique concentration of manufacturing and research players, ophthalmology coverage by ophthalmologists and hospital departments well above the national average, excellent representation by patients' associations (7) representing every pathology leading to visual impairment.

Projects already under way: creation of a low vision center in Nice, epidemiological studies in partnership with a global research network, the Institut de la Vision in Paris.

Count on a long-established pool of excellence in therapy and publicly-funded research

The Côte d'Azur is home to two major hospital referral centers:

  • referral center for vitreoretinal surgery
  • referral center for ocular oncology: Cyclotron treatment of melanomas, orbital tumors. The nuclear medicine and radiotherapy center is a leading local center of excellence in basic and clinical research.

Since 1991, the Cyclotron has been used to treat 3,500 European patients suffering from choroidal melanomas, making this the world's third largest treatment cohort.